Evaluating the prognostic impact of IDH mutations in intrahepatic cholangiocarcinoma.

Journal of Clinical Oncology 2026 Open access

Read full text
Authors: Rebecca G. Gelfer, Robert Donald Harvey, Esther N Drill, Vinod P. Balachandran, Michael Ian D'Angelica, Jeffrey A. Drebin, Peter Thomas Kingham, Lily V. Saadat, Kevin Soares, A. Wei, Ghassan K. Abou-Alfa, Andrea Cercek
+4 more James J. Harding, Eileen M. O'Reilly, Bas Groot Koerkamp, William R. Jarnagin
DOI: 10.1200/jco.2026.44.2_suppl.598
Cited by: 2

Abstract

598 Background: Mutations in isocitrate dehydrogenase 1 and 2 ( IDH1 , IDH2 ) are common in intrahepatic cholangiocarcinoma (ICC), but their prognostic value is unclear. Using a large, clinically annotated dataset, we assessed their impact in resected and non-resected ICC. Methods: This was a retrospective study of ICC patients who underwent next-generation sequencing from 2008-2022. Adults treated with curative intent resection (resected) or managed nonoperatively (unresectable) were analyzed. Results: Of 795 patients, 25% had IDH1/2 mutations (80% IDH1 , 20% IDH2 ) ( IDH mut) and 43% underwent resection. High-risk genetic alterations ( TP53 mut, KRAS mut, CDKN2A del) were more frequent in IDH wild-type ( IDH wt) ( IDH mut, OR 2.26; q

Fields of Study & Subjects

Cholangiocarcinoma and Gallbladder Cancer Studies Liver Diseases and Immunity Gallbladder and Bile Duct Disorders

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
2_suppl
Pages
598–598
Publication date
10 January 2026
Language
EN